Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Mito BioPharm General Information
Mito BioPharm is a private biopharmaceutical company focused on developing small molecule therapeutics for metabolic and oncologic diseases. Its pipeline is preclinical and targets NAFLD/NASH, type 2 diabetes, AML, metastatic colon cancer, liver cancer, and T-cell ALL. No clinical results have been reported as all programs remain in the preclinical phase.
Contact Information
Primary Industry
Biotech
Corporate Office
Piscataway, New Jersey
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
not disclosed
Mito BioPharm Funding
No funding data available
To view Mito BioPharm's complete valuation and funding history, request access »